RxDoctor Payments Data

Peter Green, MD

Gastroenterology · New York, NYNPI 1306853205

Payments from drug & device makers

$77,278in general payments, 2019–2025

Across 28 payments — averaging $2759.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Chugai Pharmaceutical Co., Ltd.$34K
  • Takeda Pharmaceuticals U.S.A., Inc.$15K
  • AbbVie$11K
  • Janssen Research & Development, LLC$10K
  • Immunogenx, Inc.$7K
  • Teva Pharmaceuticals USA, Inc.$255
  • plus $86 from 2 others
$2,408in research payments, 2019–2025

Across 1 payment — averaging $2407.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Takeda Pharmaceuticals U.S.A., Inc.$2K

What the payments were for

  • Consulting fees$25,14870%
  • Speaking & faculty fees$9,80027%
  • Travel & lodging$6642%
  • Food & beverage$2311%

General payments by program year

19
20
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$77,278 in reported general payments places this provider in the 90th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York

Medicare billing

Part B allowed, 2024
$75,762
Medicare patients
234
Services billed
446

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZenpepLipase/Protease/Amylase18$108,969
CreonLipase/Protease/Amylase23$69,563
LinzessLinaclotide17$14,060
Budesonide EcBudesonide12$4,254
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates49$3,090
Sucralfate15$2,375
CholestyramineCholestyramine (With Sugar)20$1,278
Omeprazole88$1,240
Budesonide DrBudesonide13$1,193
Famotidine58$629
Pantoprazole Sodium11$140
Amitriptyline Hcl21$107

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$10,609$83,62340 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →